{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:29:00Z","timestamp":1783405740070,"version":"3.54.6"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2026JJ80951"],"award-info":[{"award-number":["2026JJ80951"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2026JJ81500"],"award-info":[{"award-number":["2026JJ81500"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multi-target tyrosine kinase inhibitors (TKIs) are cornerstone therapies for solid malignancies, yet their association with renal thrombotic microangiopathy (TMA)\u2014a severe, irreversible adverse event\u2014remains incompletely defined. This study delineates TKI-associated renal TMA\u2019s clinical features, onset patterns, and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, Cochrane Library, and Web of Science for case reports\/series of renal TMA linked to 7 multi-target TKIs (sunitinib, sorafenib, etc.) published through January 2026. Key data were extracted and analyzed descriptively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-one cases were included (median age 62\u00a0years, 51.6% female). Common tumors: renal cell carcinoma (29.0%), thyroid cancer (16.1%), gastrointestinal stromal tumor (12.9%). Sunitinib was most implicated (48.4%). Median latency: 16\u00a0months (0.5\u201396\u00a0months); combination therapy shortened to 3.5\u00a0months. Dominant triad: hypertension (58.1%), AKI (77.4%), nephrotic proteinuria (67.9%); classic MAHA was uncommon. Kidney biopsy (87.1%) confirmed TMA. TKI discontinuation: 87.1% (6.5% dose reduction). Among evaluable patients, 90.0% improved, but 53.3% developed residual CKD and 10.0% ESRD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TKI-associated renal TMA presents as hypertension-proteinuria-AKI rather than classic hemolysis. Sunitinib confers highest risk, baseline hypertension is a key modifiable factor, and combination therapy accelerates onset. Lifelong monitoring and timely TKI discontinuation are critical, though residual CKD is common.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1834421","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:54:44Z","timestamp":1776837284000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Multi-target tyrosine kinase inhibitor-associated renal thrombotic microangiopathy: a pooled analysis of 31 cases"],"prefix":"10.3389","volume":"17","author":[{"given":"Miao","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Hunan Cancer Hospital\/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchen","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xiangya Hospital, Central South University","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41375-021-01383-2","article-title":"Endothelial dysfunction and thromboembolism in children, adolescents, and young adults with acute lymphoblastic leukemia","volume":"36","author":"Andres-Jensen","year":"2022","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"016106","DOI":"10.1063\/5.0234507","article-title":"Dysfunctional mechanotransduction regulates the progression of PIK3CA-driven vascular malformations","volume":"9","author":"Aw","year":"2025","journal-title":"APL Bioeng."},{"key":"B3","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/ndt\/gfn657","article-title":"Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib","volume":"24","author":"Boll\u00e9e","year":"2009","journal-title":"Nephrol. Dial. Transpl."},{"key":"B4","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.kint.2023.12.021","article-title":"A case-based narrative review of pregnancy-associated atypical hemolytic uremic syndrome\/complement-mediated thrombotic microangiopathy","volume":"105","author":"Che","year":"2024","journal-title":"Kidney Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e220078","DOI":"10.1530\/EO-22-0078","article-title":"Thrombotic microangiopathy associated with lenvatinib therapy","volume":"3","author":"Contreras","year":"2023","journal-title":"Endocr. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/ndt\/gfp666","article-title":"Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy","volume":"25","author":"Costero","year":"2010","journal-title":"Nephrol. Dial. Transpl."},{"key":"B7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41413-022-00229-6","article-title":"Endothelial PDGF-BB\/PDGFR-beta signaling promotes osteoarthritis by enhancing angiogenesis-dependent abnormal subchondral bone formation","volume":"10","author":"Cui","year":"2022","journal-title":"Bone Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3870\/j.issn.1004-0781.2024.06.027","article-title":"A case of renal thrombotic microangiopathy induced by anlotinib","volume":"43","author":"Dai","year":"2024","journal-title":"Her. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00428-021-03114-5","article-title":"Lenvatinib-related renal microangiopathy: a case series","volume":"480","author":"Delsante","year":"2022","journal-title":"Virchows Arch."},{"key":"B10","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ajt.2025.08.019","article-title":"Evolving landscape of thrombotic microangiopathy in kidney transplant recipients in the post-C5 inhibitor era","volume":"26","author":"Drapeau","year":"2026","journal-title":"Am. J. Transpl."},{"key":"B11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00204-024-03874-4","article-title":"Hypertension toxicity of VEGFR-TKIs in cancer treatment: incidence, mechanisms, and management strategies","volume":"99","author":"Du","year":"2025","journal-title":"Arch. Toxicol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1681\/ASN.2021030294","article-title":"Reduced glomerular filtration in diabetes is attributable to loss of density and increased resistance of glomerular endothelial cell fenestrations","volume":"33","author":"Finch","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/j.ekir.2025.04.022","article-title":"Systematic review of the outcomes and prognostic factors of patients with systemic lupus erythematosus-associated thrombotic microangiopathy","volume":"10","author":"Gai","year":"2025","journal-title":"Kidney Int. Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1053\/j.ajkd.2022.10.014","article-title":"Renal thrombotic microangiopathy: a review","volume":"81","author":"Genest","year":"2023","journal-title":"Am. J. Kidney Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e255841","DOI":"10.1136\/bcr-2023-255841","article-title":"Chronic thrombotic microangiopathy presenting as acute nephrotic syndrome in a patient with renal cancer receiving tyrosine kinase inhibitor therapy","volume":"17","author":"Ghimire","year":"2024","journal-title":"BMJ Case Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/ATVBAHA.123.320000","article-title":"Thrombomodulin regulates PTEN\/AKT signaling axis in endothelial cells","volume":"44","author":"Giri","year":"2024","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"155824","DOI":"10.1016\/j.prp.2025.155824","article-title":"Clinicopathological analysis of anti-VEGF drug-associated renal thrombotic microangiopathy: a case series and review of the literature","volume":"266","author":"Han","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"B18","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.1016\/j.transproceed.2018.07.020","article-title":"Development of focal segmental glomerulosclerosis and thrombotic microangiopathy in a liver transplant patient on sorafenib for hepatocellular carcinoma: a case report","volume":"50","author":"Hanna","year":"2018","journal-title":"Transpl. Proc."},{"key":"B19","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1681\/ASN.0000000645","article-title":"Post-transplant thrombotic microangiopathy","volume":"36","author":"Java","year":"2025","journal-title":"J. Am. Soc. Nephrol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4103\/0971-4065.107215","article-title":"Sunitinib induced nephrotic syndrome and thrombotic microangiopathy","volume":"23","author":"Jha","year":"2013","journal-title":"Indian J. Nephrol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"c312","DOI":"10.1159\/000319885","article-title":"Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature","volume":"117","author":"Jhaveri","year":"2011","journal-title":"Nephron Clin. Pract."},{"key":"B22","doi-asserted-by":"publisher","first-page":"100929","DOI":"10.1016\/j.drup.2023.100929","article-title":"Sunitinib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers","volume":"67","author":"Jin","year":"2023","journal-title":"Drug Resist Updat"},{"key":"B23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.15586\/jkcvhl.v8i1.161","article-title":"Thrombotic microangiopathy associated with pazopanib in a kidney transplant recipient","volume":"8","author":"Kalla","year":"2021","journal-title":"J. Kidney Cancer VHL"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1093\/annonc\/mdm454","article-title":"Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome","volume":"18","author":"Kapiteijn","year":"2007","journal-title":"Ann. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1136\/jcp-2024-209851","article-title":"Sunitinib induced glomerular thrombotic microangiopathy in a patient with refractory pancreatic neuroendocrine tumour","volume":"78","author":"Khan","year":"2025","journal-title":"J. Clin. Pathol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1488853","DOI":"10.3389\/fimmu.2024.1488853","article-title":"Comprehensive analysis of VEGF\/VEGFR inhibitor-induced immune-mediated hypertension: integrating pharmacovigilance, clinical data, and preclinical models","volume":"15","author":"Kuang","year":"2024","journal-title":"Front. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/nep.13086","article-title":"Cabozantinib-induced renal thrombotic microangiopathy","volume":"23","author":"La Manna","year":"2018","journal-title":"Nephrol. Carlt."},{"key":"B28","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/joim.13703","article-title":"Thrombotic microangiopathy associated with anticancer and immune system targeting drugs: new insights from real-world data using the WHO pharmacovigilance database","volume":"294","author":"Largeau","year":"2023","journal-title":"J. Intern Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/art.42681","article-title":"Clinical evaluation and management of thrombotic microangiopathy","volume":"76","author":"Leisring","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/ndtplus\/sfn013","article-title":"Thrombotic microangiopathy associated with sunitinib, a VEGF inhibitor, in a patient with factor V Leiden mutation","volume":"1","author":"Levey","year":"2008","journal-title":"NDT Plus"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.kint.2024.02.014","article-title":"Assessment of epidemiology and outcomes of adult patients with kidney-limited thrombotic microangiopathies","volume":"105","author":"Maisons","year":"2024","journal-title":"Kidney Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ymthe.2025.10.001","article-title":"Podocyte-directed VEGFC gene therapy prevents increased glomerular permeability and glycocalyx damage in experimental type 1 diabetes","volume":"34","author":"Martin Alonso","year":"2026","journal-title":"Mol. Ther."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1088031","DOI":"10.3389\/fphar.2022.1088031","article-title":"Drug-induced thrombotic microangiopathy: an updated review of causative drugs, pathophysiology, and management","volume":"13","author":"Mazzierli","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.2169\/internalmedicine.8365-21","article-title":"Thrombotic microangiopathy, podocytopathy, and damage to the renal tubules with severe proteinuria and acute renal dysfunction induced by Lenvatinib","volume":"61","author":"Nakashima","year":"2022","journal-title":"Intern Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.6004\/jnccn.2023.7047","article-title":"Early increases in blood pressure and major adverse cardiovascular events in patients with renal cell carcinoma and thyroid cancer treated with VEGFR TKIs","volume":"21","author":"Narayan","year":"2023","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4103\/0973-1482.172575","article-title":"Sunitinib-induced thrombotic microangiopathy","volume":"12","author":"Noronha","year":"2016","journal-title":"J. Cancer Res. Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13046-021-01961-3","article-title":"Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma","volume":"40","author":"Sharma","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e56660","DOI":"10.7759\/cureus.56660","article-title":"A case of acute kidney injury, proteinuria, and thrombotic microangiopathy associated with sunitinib therapy in metastatic pancreatic neuroendocrine tumor","volume":"16","author":"Singh","year":"2024","journal-title":"Cureus"},{"key":"B40","doi-asserted-by":"publisher","first-page":"4327904","DOI":"10.1155\/2018\/4327904","article-title":"Thrombotic thrombocytopenic purpura associated with pazopanib","volume":"2018","author":"Syed","year":"2018","journal-title":"Case Rep. Hematol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1097\/MJT.0b013e3181eefe8b","article-title":"Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome","volume":"19","author":"Talebi","year":"2012","journal-title":"Am. J. Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-024-01899-w","article-title":"Therapeutic advances of targeting receptor tyrosine kinases in cancer","volume":"9","author":"Tomuleasa","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1016\/j.humpath.2014.05.015","article-title":"Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature","volume":"45","author":"Usui","year":"2014","journal-title":"Hum. Pathol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"100690","DOI":"10.1016\/j.modpat.2024.100690","article-title":"Etiology and outcomes of kidney-limited and systemic thrombotic microangiopathy","volume":"38","author":"van Doorn","year":"2025","journal-title":"Mod. Pathol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2644681","DOI":"10.1080\/19490976.2026.2644681","article-title":"Gut microbiota metabolic reprogramming drives the development of metabolic diseases in the host","volume":"18","author":"Wang","year":"2026","journal-title":"Gut Microbes"},{"key":"B46","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3969\/j.issn.1672-3384.2019.10.019","article-title":"A case report of renal limited thrombotic microangiopathy and nephrotic syndrome induced by sunitiniband","volume":"17","author":"Wu","year":"2019","journal-title":"Clin. Med. J."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1420377","DOI":"10.3389\/fphar.2024.1420377","article-title":"Renal microangiopathy induced by lenvatinib in hepatocellular carcinoma: a case report and literature review","volume":"15","author":"Xue","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00467-016-3355-z","article-title":"Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome","volume":"31","author":"Y\u0131lmaz","year":"2016","journal-title":"Pediatr. Nephrol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12882-021-02656-9","article-title":"Regorafenib-induced renal-limited thrombotic microangiopathy: a case report and review of literature","volume":"23","author":"Yin","year":"2022","journal-title":"BMC Nephrol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40779-023-00442-2","article-title":"Pericytes protect rats and mice from sepsis-induced injuries by maintaining vascular reactivity and barrier function: implication of miRNAs and microvesicles","volume":"10","author":"Zhang","year":"2023","journal-title":"Mil. Med. Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12882-024-03732-6","article-title":"Sunitinib-induced endocapillary proliferative glomerulonephritis with IgA2 deposit in addition to thrombotic microangiopathy: a case report","volume":"25","author":"Zhang","year":"2024","journal-title":"BMC Nephrol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s12882-025-04303-z","article-title":"Case report: nephrotic syndrome induced by Lenvatinib treatment in a patient with von Hippel-Lindau syndrome","volume":"26","author":"Zhang","year":"2025","journal-title":"BMC Nephrol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1834421\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:54:51Z","timestamp":1776837291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1834421\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":52,"alternative-id":["10.3389\/fphar.2026.1834421"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1834421","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"1834421"}}